Dilated Cardiomyopathy (DCM)
Cardiovascular·MeSH: Cardiomyopathy, Dilated
Prevalence
30.0 / 100K
4 drugs in development·3 companies·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| SGT-701 | Solid Biosciences Inc. (SLDB) |
Phase 2(1)
| Drug | Company |
|---|---|
| danicamtiv | MyoKardia, Inc. (MYOK) |
Preclinical(1)
| Drug | Company |
|---|---|
| act-1 | MyoKardia, Inc. (MYOK) |
Unknown(1)
| Drug | Company |
|---|---|
| laromestrocel | Longeveron Inc. (LGVN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Dilated Cardiomyopathy (DCM)?
BioSniper tracks 4 drugs in development for Dilated Cardiomyopathy (DCM) across 3 companies.
How many clinical trials target Dilated Cardiomyopathy (DCM)?
There are 2 clinical trials targeting Dilated Cardiomyopathy (DCM) tracked by BioSniper.
What is the prevalence of Dilated Cardiomyopathy (DCM)?
The estimated prevalence of Dilated Cardiomyopathy (DCM) is approximately 30.0 per 100,000 population.
Deep-dive into Dilated Cardiomyopathy (DCM)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis